Table 2 Efficacy outcomes after 28 days of follow-up
Efficacy outcomes | Chemoprevention arm | |||
|---|---|---|---|---|
No chemoprevention (n = 992) | Monthly SP (n = 901) | Daily TS (n = 721) | Monthly DP (n = 444) | |
Fever clearancea, n (%) | ||||
Fever present on day 1 | 497 (50.2%) | 445 (49.5%) | 339 (47.0%) | 203 (46.1%) |
Fever present on day 2 | 73 (7.4%) | 87 (9.7%) | 58 (8.1%) | 32 (7.3%) |
Fever present on day 3 | 37 (3.9%) | 32 (3.7%) | 20 (2.9%) | 16 (3.8%) |
Parasite clearance, n (%) | ||||
Positive blood smear on day 2 | 54 (5.5%) | 51 (5.7%) | 35 (4.9%) | 24 (5.5%) |
Positive blood smear on day 3 | 5 (0.5%) | 4 (0.5%) | 4 (0.6%) | 6 (1.4%) |
WHO treatment outcome, n (%) | ||||
No outcome | 29 (2.9%) | 25 (2.8%) | 24 (3.3%) | 16 (3.6%) |
Early treatment failure | 1 (0.1%) | 8 (0.9%) | 4 (0.6%) | 3 (0.7%) |
Late clinical failure | 172 (17.3%) | 148 (16.4%) | 112 (15.5%) | 71 (16.0%) |
Late parasitological failure | 284 (28.6%) | 240 (26.6%) | 190 (26.4%) | 115 (25.9%) |
Adequate clinical and parasitological response | 506 (51.0%) | 480 (53.3%) | 391 (54.2%) | 239 (53.8%) |
Appearance of gametocytesb, n (%) | 33 (3.5%) | 33 (3.8%) | 24 (3.6%) | 16 (3.7%) |
Haemoglobin recoveryc g/dL, mean (SD) | 0.5 (1.3) | 0.5 (1.2) | 0.6 (1.2) | 0.6 (1.1) |